Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAPOX + FOLFOX (University Hospital of Larissa)
- Development stage
- Unknown
- Lead developer
- University Hospital of Larissa
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Consolidation chemotherapy refers to the administration of systemic chemotherapy after neoadjuvant chemoradiotherapy but prior to surgery in patients with locally advanced rectal cancer. In the specific trial conducted by Larissa University Hospital (NCT02795819), this regimen consists of either CAPOX (capecitabine and oxaliplatin) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin). This strategy is a component of Total Neoadjuvant Therapy (TNT), designed to improve the rate of pathological complete response and provide early treatment of systemic micrometastases. Oxaliplatin acts as a cytotoxic agent by forming DNA adducts, while fluoropyrimidines like capecitabine and 5-fluorouracil inhibit thymidylate synthase, thereby disrupting DNA synthesis.
- Other names
- consolidation chemotherapy-Larissa University Hospital-rectal cancerConsolidation ChemotherapyCAPOXFOLFOXXELOX
02
Targets
TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on CAPOX + FOLFOX (University Hospital of Larissa).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAPOX + FOLFOX (University Hospital of Larissa).